Inclusive of all taxes
Sofosbuvir and daclatasvir tablets I.P are a potent combination antiviral medication specifically formulated for the treatment of chronic hepatitis C virus (HCV) infection. This combination therapy works by inhibiting HCV replication at different stages, thus improving treatment efficacy and reducing viral load efficiently. Designed for oral administration, these tablets are utilized by healthcare professionals to manage and potentially cure patients suffering from varying genotypes of hepatitis C. With an emphasis on safety and tolerability, Sofosbuvir and daclatasvir tablets help reduce liver inflammation and prevent progression to advanced liver diseases like cirrhosis and hepatocellular carcinoma. The formulation complies with Indian Pharmacopoeia (I.P) standards ensuring high quality, purity, and consistent therapeutic action required for clinical use in the Indian healthcare market.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Sofosbuvir and Daclatasvir |
| Indication | Chronic Hepatitis C Virus (HCV) Infection |
| Pharmacological Action | Direct-acting antiviral agents inhibiting HCV RNA polymerase and NS5A protein |
| Dosage Form | Oral Tablets |
| Compliance Standard | Indian Pharmacopoeia (I.P) Certified |
| Treatment Efficacy | Highly effective across multiple HCV genotypes |
| Safety Profile | Well tolerated with minimal side effects |
| Therapeutic Use | Used for viral clearance and preventing liver disease progression |
| Storage Condition | Store in a cool, dry place away from direct sunlight |
| Attributes | Description |
|---|---|
| Sofosbuvir Content | 400 mg per tablet |
| Daclatasvir Content | 60 mg per tablet |
| Tablet Shape | Film-coated, oval-shaped |
| Packaging | Blister packs of 10 or 30 tablets |
| Shelf Life | 24 months from manufacturing date |
| Storage Temperature | 15°C to 30°C |
| Regulatory Standard | I.P - Indian Pharmacopoeia |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Sofosbuvir inhibits the HCV RNA-dependent RNA polymerase (NS5B), while daclatasvir targets the NS5A protein, thereby preventing viral replication and assembly.
Yes, Sofosbuvir and daclatasvir tablets have proven efficacy across multiple HCV genotypes, making them suitable for broad-spectrum antiviral therapy.
These tablets are available in blister packs containing 10 or 30 tablets per pack, suitable for bulk medical use.
The product conforms to Indian Pharmacopoeia (I.P) standards, ensuring quality, purity, and therapeutic consistency.
They should be stored in a cool, dry place with temperatures between 15°C and 30°C, away from direct light and moisture.
Country Of Origin: India
Sofosbuvir and daclatasvir is used in the treatment of chronic hepatitis C virus (HCV) infection .
Inclusive of all taxes
You Save: 0
